Severe food allergy incidence has increased significantly in the US in the last 40 years. This can be life threatening and cause significant decreases in QOL. Although immunotherapy can help many patients still have severe reactions when accidentally exposed to the allergen in question. A new study looks at the utility of omalizumab in preventing food allergy reactions. We also review the new AAAAI guidelines on anaphylaxis with an update for pharmacists and primary providers. 

THE GAMECHANGER: A new study looks at the utility of omalizumab in preventing food allergy reactions after accidental exposure. 

Upon successful completion of this course, learners should be able to:
1. Discuss the OUtMATCH study results and their relevance to patients with food allergies.
2. Interpret the new AAAAI anaphylaxis guidelines in relation to patient care.

Geoffrey C. Wall, PharmD, FCCP, BCPS, CG
Professor of Clinical Sciences
Drake University College of Pharmacy and Health Sciences

Dr. Wall is a member of the Janssen Speaker’s Bureau. All relevant financial relationships have been mitigated.  

Course fee includes course, course materials, and CPE credit submission to CPE Monitor.
Course is non-refundable.
Release Date: March 18, 2024
Planned Expiration Date: March 18, 2025

Copyright 2023, CEimpact. All Rights Reserved. Any reproduction of this course without express permission is strictly forbidden.